Research programme: fully human monoclonal antibodies - Celldex Therapeutics

Drug Profile

Research programme: fully human monoclonal antibodies - Celldex Therapeutics

Alternative Names: CR 010; CR 011; CR 012; CR 031; CR 039; CR 064

Latest Information Update: 16 Mar 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen; CuraGen Corporation
  • Developer Amgen; Celldex Therapeutics Inc; CuraGen Corporation
  • Class Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Membrane protein inhibitors; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Inflammation

Most Recent Events

  • 02 Oct 2009 CuraGen Corporation has been acquired by Celldex Therapeutics Inc
  • 03 Apr 2006 Abgenix has been acquired and merged into Amgen
  • 08 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top